BR112019004639A2 - formulações de 4-metil-5-(pirazin-2-il)-3h-1,2-ditiol-3-tiona, formulações de gosto modificado e métodos para produzir e usar as mesmas - Google Patents
formulações de 4-metil-5-(pirazin-2-il)-3h-1,2-ditiol-3-tiona, formulações de gosto modificado e métodos para produzir e usar as mesmasInfo
- Publication number
- BR112019004639A2 BR112019004639A2 BR112019004639A BR112019004639A BR112019004639A2 BR 112019004639 A2 BR112019004639 A2 BR 112019004639A2 BR 112019004639 A BR112019004639 A BR 112019004639A BR 112019004639 A BR112019004639 A BR 112019004639A BR 112019004639 A2 BR112019004639 A2 BR 112019004639A2
- Authority
- BR
- Brazil
- Prior art keywords
- formulations
- producing
- taste
- thione
- dithiol
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title abstract 5
- 238000000034 method Methods 0.000 title abstract 2
- CKNAQFVBEHDJQV-UHFFFAOYSA-N oltipraz Chemical compound S1SC(=S)C(C)=C1C1=CN=CC=N1 CKNAQFVBEHDJQV-UHFFFAOYSA-N 0.000 title abstract 2
- 238000009472 formulation Methods 0.000 title 2
- 239000013078 crystal Substances 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
- 238000012986 modification Methods 0.000 abstract 1
- 230000004048 modification Effects 0.000 abstract 1
- 229950008687 oltipraz Drugs 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
- A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/38—Cellulose; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Inorganic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Dispersion Chemistry (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IN201611031046 | 2016-09-12 | ||
| IN201611031045 | 2016-09-12 | ||
| US201662412701P | 2016-10-25 | 2016-10-25 | |
| PCT/IB2017/001231 WO2018047002A1 (en) | 2016-09-12 | 2017-09-12 | Formulations of 4-methyl-5-(pyrazin-2-yl)-3h-1.2-dithiole-3-thione, taste-modified formulations, and methods of making and using same |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112019004639A2 true BR112019004639A2 (pt) | 2019-07-16 |
Family
ID=60569946
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112019004639A BR112019004639A2 (pt) | 2016-09-12 | 2017-09-12 | formulações de 4-metil-5-(pirazin-2-il)-3h-1,2-ditiol-3-tiona, formulações de gosto modificado e métodos para produzir e usar as mesmas |
Country Status (9)
| Country | Link |
|---|---|
| US (2) | US11185544B2 (enExample) |
| EP (1) | EP3509641A1 (enExample) |
| JP (2) | JP2019533008A (enExample) |
| KR (1) | KR20190089851A (enExample) |
| CN (1) | CN109996563A (enExample) |
| AU (1) | AU2017322544B2 (enExample) |
| BR (1) | BR112019004639A2 (enExample) |
| CA (1) | CA3036630A1 (enExample) |
| PH (1) | PH12019500530A1 (enExample) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3509642A1 (en) * | 2016-09-12 | 2019-07-17 | ST IP Holding AG | Formulations of 4-methyl-5-(pyrazin-2-yl)-3h-1, 2-dithiole-3-thione, and methods of making and using same |
| US11260604B2 (en) * | 2018-03-14 | 2022-03-01 | Andrew Reynolds | Method and system for dispensing molten wax into molds by means of a desktop apparatus |
Family Cites Families (33)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7067116B1 (en) | 2000-03-23 | 2006-06-27 | Warner-Lambert Company Llc | Fast dissolving orally consumable solid film containing a taste masking agent and pharmaceutically active agent at weight ratio of 1:3 to 3:1 |
| CA2408152A1 (en) * | 2000-05-05 | 2001-11-15 | Wisconsin Alumni Research Foundation | Compositions and methods for protecting cells during cancer chemotherapy and radiotherapy |
| US7012148B2 (en) | 2001-09-25 | 2006-03-14 | Trustees Of Dartmouth College | Compositions and methods for thionation during chemical synthesis reactions |
| US7199122B2 (en) | 2001-10-02 | 2007-04-03 | Fox Chase Cancer Center | Methods for inhibiting angiogenesis |
| DE60309834D1 (de) | 2002-02-13 | 2007-01-04 | Solvay Pharma | Verwendung von anethol-dithiolethion zur vorbeugung von lungenkrebs |
| KR100491318B1 (ko) * | 2002-11-26 | 2005-05-24 | 씨제이 주식회사 | 올티프라즈(Oltipraz) 제조방법 |
| KR20050014960A (ko) * | 2003-08-01 | 2005-02-21 | 씨제이 주식회사 | B형 간염 치료 및 간 조직 재생용 약제학적 조성물 |
| DE602004005617T2 (de) | 2003-12-22 | 2007-12-13 | Alcon Inc. | Mittel zur behandlung von glaukomatöser retinopathie und optischer neuropathie |
| KR100629771B1 (ko) * | 2004-01-27 | 2006-09-28 | 씨제이 주식회사 | 결정성이 감소되거나 무정형화된 올티프라즈의 제조방법 |
| LT2522365T (lt) * | 2004-11-24 | 2017-02-10 | Meda Pharmaceuticals Inc. | Kompozicijos, apimančios azelastiną, ir jų panaudojimo būdai |
| FR2879444B1 (fr) | 2004-12-22 | 2007-05-18 | Oreal | Utilisation d'un compose capable d'augmenter le taux de glutathion dans les melanocytes pour le traitement de la canitie |
| US20070036733A1 (en) | 2005-08-12 | 2007-02-15 | Takasago International Corp. (Usa) | Sensation masking composition |
| CN101257949B (zh) | 2005-08-15 | 2011-01-19 | 奇华顿股份有限公司 | 清凉化合物 |
| US7803353B2 (en) | 2006-03-29 | 2010-09-28 | The Procter & Gamble Company | Oral care compositions having improved consumer aesthetics and taste |
| GB0704718D0 (en) | 2007-03-12 | 2007-04-18 | Prendergast Patrick T | Compounds and methods for preventing and treating mucositis |
| ATE540667T1 (de) | 2007-06-13 | 2012-01-15 | Givaudan Sa | Verbindungen mit kühlender wirkung |
| WO2009014624A2 (en) | 2007-07-20 | 2009-01-29 | Johns Hopkins University | Nrf2 inducers for treating epidermolysis bullosa simplex |
| WO2009099830A2 (en) | 2008-01-31 | 2009-08-13 | Mcneil-Ppc, Inc. | Edible film-strips for immediate release of active ingredients |
| WO2009114525A1 (en) | 2008-03-10 | 2009-09-17 | University Of Louisville Research Foundation, Inc. | Methods and compositions for controlled delivery of phytochemical agents |
| US8858995B2 (en) | 2008-03-10 | 2014-10-14 | University Of Louisville Research Foundation, Inc. | Methods and compositions for controlled delivery of phytochemical agents |
| KR101057485B1 (ko) | 2008-08-04 | 2011-08-17 | 서울대학교산학협력단 | 1,2-디티올티온 유도체를 함유하는 엘엑스알-알파 과다발현으로 인한 질병의 예방 및 치료용 약학 조성물 |
| EP2427170A2 (en) | 2009-05-05 | 2012-03-14 | Givaudan SA | Organic compounds having cooling properties |
| EP2717860A4 (en) * | 2011-06-08 | 2014-11-05 | Sti Pharma Llc | FORMULATION FROM A WATER SOLUBLE AND PHARMACEUTICALLY ACTIVE ORGANIC COMPOUND WITH CONTROLLED ABSORPTION FOR ONLY DAILY APPLICATION |
| ES2632443T3 (es) * | 2011-09-22 | 2017-09-13 | Viiv Healthcare Uk Limited | Compuestos de pirrolopiridinona y procedimientos de tratamiento del VIH |
| CN105007898A (zh) | 2012-12-19 | 2015-10-28 | 卡希夫制药有限责任公司 | 难溶性药物的过饱和的稳定纳米颗粒 |
| US20160206641A1 (en) | 2013-08-16 | 2016-07-21 | Luminus Biosciences Inc. | Rapidly-dissolving thin film formulation of water soluble digitalis glycoside for the treatment of congestive heart disease |
| AU2015222884A1 (en) | 2014-02-27 | 2016-08-04 | The Procter & Gamble Company | Oral care compositions with a reduced bitter taste perception |
| WO2016207914A2 (en) | 2015-06-25 | 2016-12-29 | St Ip Holding Ag | Methods for preparing oltipraz |
| US20160376259A1 (en) * | 2015-06-25 | 2016-12-29 | St Ip Holding Ag | Methods for Preparing Oltipraz |
| ITUB20159655A1 (it) | 2015-12-23 | 2017-06-23 | Bormioli Rocco Spa | Capsula di sicurezza di un contenitore. |
| ITUA20162141A1 (it) | 2016-03-31 | 2017-10-01 | Bormioli Pharma Spa | Capsula di chiusura |
| EP3509642A1 (en) * | 2016-09-12 | 2019-07-17 | ST IP Holding AG | Formulations of 4-methyl-5-(pyrazin-2-yl)-3h-1, 2-dithiole-3-thione, and methods of making and using same |
| KR20180123796A (ko) | 2017-05-10 | 2018-11-20 | 서울대학교산학협력단 | Nrf2-NEMO 경로 활성화를 통한 과중력으로 인한 세포괴사의 억제용 조성물 및 방법 |
-
2017
- 2017-09-12 AU AU2017322544A patent/AU2017322544B2/en not_active Expired - Fee Related
- 2017-09-12 CN CN201780069887.1A patent/CN109996563A/zh active Pending
- 2017-09-12 BR BR112019004639A patent/BR112019004639A2/pt not_active IP Right Cessation
- 2017-09-12 KR KR1020197010518A patent/KR20190089851A/ko not_active Ceased
- 2017-09-12 CA CA3036630A patent/CA3036630A1/en active Pending
- 2017-09-12 EP EP17808566.8A patent/EP3509641A1/en active Pending
- 2017-09-12 JP JP2019535991A patent/JP2019533008A/ja active Pending
-
2019
- 2019-03-12 US US16/351,122 patent/US11185544B2/en active Active
- 2019-03-12 PH PH12019500530A patent/PH12019500530A1/en unknown
-
2021
- 2021-10-25 US US17/509,965 patent/US20220296589A1/en not_active Abandoned
-
2023
- 2023-05-09 JP JP2023077049A patent/JP2023113634A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| JP2019533008A (ja) | 2019-11-14 |
| PH12019500530A1 (en) | 2020-02-24 |
| AU2017322544A1 (en) | 2019-05-02 |
| JP2023113634A (ja) | 2023-08-16 |
| EP3509641A1 (en) | 2019-07-17 |
| US20220296589A1 (en) | 2022-09-22 |
| US11185544B2 (en) | 2021-11-30 |
| US20190209557A1 (en) | 2019-07-11 |
| KR20190089851A (ko) | 2019-07-31 |
| CA3036630A1 (en) | 2018-03-15 |
| AU2017322544B2 (en) | 2022-06-02 |
| CN109996563A (zh) | 2019-07-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2019001125A (es) | Inhibidores de cinasa macrociclica. | |
| CO2017013408A2 (es) | Compuestos bicíclicos heterocíclicos como agentes antituberculares. | |
| MX2018005315A (es) | Composiciones y metodos para el tratamiento del cancer. | |
| BR112018008877A2 (pt) | inibidores de ret | |
| CO2017004525A2 (es) | Dihidropirrolopiridinas inhibidoras de ror-gamma | |
| CO2018000631A2 (es) | Compuestos bicíclicos como inhibidores de atx | |
| MX2017011269A (es) | Inhibidores de lisil oxidasa tipo 2 fluorinados y usos de los mismos. | |
| CO2017005784A2 (es) | Compuestos bicíclicos fusionados para el tratamiento de enfermedades | |
| BR112017012342A2 (pt) | compostos inibitórios de bcl-xl e conjugados de anticorpo-fármaco incluindo os mesmos | |
| BR112015032736A2 (pt) | inibidores de bromodomínio cristalino | |
| CL2018000596A1 (es) | Nuevos compuestos bicíclicos como inhibidores de la atx | |
| MX2020006612A (es) | Compuesto que funciona como inhibidor de proteína de bromodominio y composición. | |
| MX2016002077A (es) | Inhibidores de la proteína regulada por glucosa 94 (gpr94) selectivos y usos de los mismos. | |
| DOP2010000304A (es) | Composiciones y metodos de preparacion y uso de las mismas | |
| CL2019002251A1 (es) | Anticuerpos contra triptasa, composiciones de estos y usos de estos. | |
| MX2018009325A (es) | Compuestos y metodos para tratar enfermedades mediadas por el acido ribonucleico (arn). | |
| AU2017228405A8 (en) | Small molecule IRE1-alpha inhibitors | |
| ECSP17026210A (es) | Compuestos de aminopurina sustituida, composiciones del mismo, y métodos de tratamiento con los mismos | |
| BR112017025711A2 (pt) | ?composições, processo para preparação de siloxanos modificados por poliéter e uso das composições inovadoras? | |
| BR112018014590A2 (pt) | formulações/composições compreendendo um inibidor de btk | |
| BR112017012504A2 (pt) | derivados de piperidina como inibidores de hdac1/2 | |
| MX2019014772A (es) | Formulaciones en gel de bisfosfocinas y usos de estas. | |
| BR112018009745A8 (pt) | compostos heterocíclicos para o tratamento de doença | |
| EA202090732A1 (ru) | Составы для трансдермального введения | |
| MX2019001225A (es) | Compuesto aromatico heterociclico nitrogenoso, metodo de preparacion del mismo, composicion farmaceutico del mismo y aplicacion del mismo. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B06W | Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette] | ||
| B350 | Update of information on the portal [chapter 15.35 patent gazette] | ||
| B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE A 6A ANUIDADE. |
|
| B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2739 DE 04-07-2023 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013. |